CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S324
DOI: 10.1055/s-0038-1640841
Abstracts
Rhinologie: Rhinology

Outcome of longtime treatment with omalizumab in patients with CRSwNP

U Förster-Ruhrmann
1   HNO-Klinik, CVK/CCM, Charité Universitätsmedizin, Berlin
,
J Kim
2   HNO-Klinik, Charité Universitätsmedizin, Berlin
,
F Raphael
2   HNO-Klinik, Charité Universitätsmedizin, Berlin
,
H Olze
2   HNO-Klinik, Charité Universitätsmedizin, Berlin
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction:

    In patients with chronic rhinosinusitis with nasal polyps (CRSwNP), asthma/aspirin intolerance the therapy is often complicated by repeated nasal polyps. Biological treatment is in these patients a new therapy. The aim of the study was the examination of a longtime follow-up examination of omalizumab in CRSwNP patients.

    Methods:

    Ten patients were included in the longtime follow-up examination (6 female, 4 male, mean age 46 years). The frequency of asthma, aspirin-intolerance, allergies, urticaria, the nasal polyp-score, the response and the tolerability of the treatment were evaluated.

    Results:

    The mean duration of therapy with omalizumab was 16 months (minimum 12 months, maximum 24 months). The mean dosage of omalizumab was 300 mg. All included patients had also asthma (100%), aspirin intolerance in 70%, allergies in 50% and chronic urticaria in 40% of the cases. The mean number of nasal sinus surgeries before treatment with omalizumab was 4. The nasal polyp score decreased during the study significantly (p = 0.01), the chronic urticaria decreased completely, exacerbations of asthma were not detected. The need of antibiotic treatment regarding acute exacerbations of rhinosinusitis decreased significantly (p = 0.02). No nasal sinus operation was performed during the longtime follow-up examination. Regarding the tolerability one patient suffered more infections following the first injections of treatment, but the therapy was continued.

    Conclusion:

    The longtime treatment with omalizumab is highly effective in patients with severe CRSwNP. There is a need for further examinations.


    #

    No conflict of interest has been declared by the author(s).

    Dr. Ulrike Förster-Ruhrmann
    HNO-Klinik, CVK/CCM, Charité Universitätsmedizin B,
    Augustenburger Platz 1, 13353,
    Berlin

    Publication History

    Publication Date:
    18 April 2018 (online)

    © 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York